Rigel Pharmaceuticals - Best Pharma Stocks of 2007

Company: Rigel Pharmaceuticals
Starting stock price: $11.89
Ending stock price: $25.39
Percent Change: 113.54%

Details: Rigel has a number of drug candidates in its pipeline. R788 is in Phase II trials for rheumatoid arthritis, ITP and B-cell lymphoma. It's also partnering with Merck Serono on the Phase II compound R763 for solid tumors and leukemia. Additionally, Rigel and Pfizer are developing R343 for asthma.

More News:
Merck Serono exercises option to Rigel's R763. Report
Serono seals oncology drug pact with Rigel. Report

Rigel Pharmaceuticals - Best Pharma Stocks of 2007
Read more on

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.